194 related articles for article (PubMed ID: 23215813)
1. Metabolism of the antituberculosis drug ethionamide.
Vale N; Gomes P; Santos HA
Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
[TBL] [Abstract][Full Text] [Related]
2. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.
Schaaf HS; Victor TC; Venter A; Brittle W; Jordaan AM; Hesseling AC; Marais BJ; van Helden PD; Donald PR
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1355-9. PubMed ID: 19861006
[TBL] [Abstract][Full Text] [Related]
3. Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites.
Laborde J; Deraeve C; Duhayon C; Pratviel G; Bernardes-Génisson V
Org Biomol Chem; 2016 Sep; 14(37):8848-8858. PubMed ID: 27714216
[TBL] [Abstract][Full Text] [Related]
4. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
[TBL] [Abstract][Full Text] [Related]
5. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
[TBL] [Abstract][Full Text] [Related]
6. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator.
Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR
Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620
[TBL] [Abstract][Full Text] [Related]
7. Radiometric vs. agar proportion methods for assessing ethionamide resistance and its clinical effects in multidrug-resistant tuberculosis.
Cimen NO; Arslan Z; Saygi A; Ocak K; Babacan F; Kurutepe M
Int J Tuberc Lung Dis; 2009 Jul; 13(7):907-13. PubMed ID: 19555543
[TBL] [Abstract][Full Text] [Related]
8. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.
Brossier F; Veziris N; Truffot-Pernot C; Jarlier V; Sougakoff W
Antimicrob Agents Chemother; 2011 Jan; 55(1):355-60. PubMed ID: 20974869
[TBL] [Abstract][Full Text] [Related]
9. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
Choi J; Park SJ; Jee JG
Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation.
Wang XD; Gu J; Wang T; Bi LJ; Zhang ZP; Cui ZQ; Wei HP; Deng JY; Zhang XE
Mol Microbiol; 2011 Dec; 82(6):1375-91. PubMed ID: 22026918
[TBL] [Abstract][Full Text] [Related]
11. Can inhA mutation predict ethionamide resistance?
Vadwai V; Ajbani K; Jose M; Vineeth VP; Nikam C; Deshmukh M; Shetty A; Soman R; Rodrigues C
Int J Tuberc Lung Dis; 2013 Jan; 17(1):129-30. PubMed ID: 23146620
[TBL] [Abstract][Full Text] [Related]
12. Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand.
Boonaiam S; Chaiprasert A; Prammananan T; Leechawengwongs M
Clin Microbiol Infect; 2010 Apr; 16(4):396-9. PubMed ID: 19486070
[TBL] [Abstract][Full Text] [Related]
13. Activation of the pro-drug ethionamide is regulated in mycobacteria.
Baulard AR; Betts JC; Engohang-Ndong J; Quan S; McAdam RA; Brennan PJ; Locht C; Besra GS
J Biol Chem; 2000 Sep; 275(36):28326-31. PubMed ID: 10869356
[TBL] [Abstract][Full Text] [Related]
14. Mutation in Eth A protein of Mycobacterium tuberculosis conferred drug tolerance against enthinoamide in Mycobacterium smegmatis mc
Anand PK; Kumar A; Saini A; Kaur J
Comput Biol Chem; 2022 Jun; 98():107677. PubMed ID: 35397466
[TBL] [Abstract][Full Text] [Related]
15. Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria.
Hanoulle X; Wieruszeski JM; Rousselot-Pailley P; Landrieu I; Locht C; Lippens G; Baulard AR
J Antimicrob Chemother; 2006 Oct; 58(4):768-72. PubMed ID: 16895935
[TBL] [Abstract][Full Text] [Related]
16. Xanthates: Metabolism by Flavoprotein-Containing Monooxygenases and Antimycobacterial Activity.
Yanev SG; Stoyanova TD; Valcheva VV; Ortiz de Montellano PR
Drug Metab Dispos; 2018 Aug; 46(8):1091-1095. PubMed ID: 29777023
[TBL] [Abstract][Full Text] [Related]
17. A review of the use of ethionamide and prothionamide in childhood tuberculosis.
Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2016 Mar; 97():126-36. PubMed ID: 26586647
[TBL] [Abstract][Full Text] [Related]
18. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria.
Vilchèze C; Weisbrod TR; Chen B; Kremer L; Hazbón MH; Wang F; Alland D; Sacchettini JC; Jacobs WR
Antimicrob Agents Chemother; 2005 Feb; 49(2):708-20. PubMed ID: 15673755
[TBL] [Abstract][Full Text] [Related]
19. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
Umubyeyi A; Rigouts L; Shamputa IC; Dediste A; Struelens M; Portaels F
Int J Infect Dis; 2008 Mar; 12(2):152-6. PubMed ID: 17950021
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
Costa-Gouveia J; Pancani E; Jouny S; Machelart A; Delorme V; Salzano G; Iantomasi R; Piveteau C; Queval CJ; Song OR; Flipo M; Deprez B; Saint-André JP; Hureaux J; Majlessi L; Willand N; Baulard A; Brodin P; Gref R
Sci Rep; 2017 Jul; 7(1):5390. PubMed ID: 28710351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
